Pharmaceuticals

FDA approves Lilly’s Xanla to treat early symptoms of Alzheimer’s disease

bexib
By bexib 0 Min Read

According to the company, Xanra is the first amyloid plaque-targeted therapy that allows treatment to be discontinued once plaque is removed.

You Might Also Like

Making Patient Data Actionable: Q&A with Noga Leviner

FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701 for the Treatment of Patients with ABCC6 Deficiency

UK MRC and AstraZeneca collaborate on translational clinical research

Is there a correlation between medical debt and delayed mental health care in the United States?

The pharmaceutical companies are losing IRA lawsuits one after another. They continue to litigate.

Share This Article
Previous Article UniCredit Bank’s Schulze speaks at Bank Automation Summit Europe 2024
Next Article Hack Club! Launches Foundation to Support Thousands of Teen Creators Around the World
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Toyota Financial Services Three ways to utilize next -generation AI
Banking
HSBC shuts down cross-border payments app
Banking
Fiserv appoints PNC Lions chairman to replace Bisignano
Banking
2025 Blueprint: American-Made Infrastructure
Manufacturing